Related by context. All words. (Click for frequent words.) 78 neoadjuvant therapy 78 chemoradiotherapy 77 neoadjuvant 77 preoperative chemotherapy 76 adjuvant radiotherapy 75 adjuvant chemotherapy 75 adjuvant therapy 75 neoadjuvant treatment 74 chemoradiation 73 postoperative chemotherapy 73 adjuvant radiation 73 locoregional 73 metastatic RCC 72 Doxil ® 72 curative resection 72 metastatic renal cell carcinoma 72 liver metastases 72 pCR 72 tumor recurrence 71 sentinel lymph node biopsy 71 resectable 71 pancreatic adenocarcinoma 71 carboplatin paclitaxel 71 EBRT 71 locoregional recurrence 71 stage IIIB 71 cystectomy 71 FOLFOX4 70 distant metastases 70 taxane therapy 70 androgen deprivation 70 lymphadenectomy 70 HER2 positive metastatic breast 70 biochemical recurrence 70 epirubicin 70 PSADT 70 chemoradiation therapy 70 trastuzumab 70 axillary dissection 70 concurrent chemoradiation 70 heavily pretreated patients 70 adjuvant tamoxifen 69 ABVD 69 clinically localized prostate 69 debulking surgery 69 postoperative radiotherapy 69 radical nephrectomy 69 cytoreduction 69 TACE 69 pegylated liposomal doxorubicin 69 biochemical relapse 69 fluorouracil 69 gemcitabine chemotherapy 69 histologically confirmed 69 Neoadjuvant 69 tumor resection 69 tamoxifen therapy 69 docetaxel 69 5FU 68 ASCT 68 cytoreductive surgery 68 recurrent glioblastoma multiforme 68 external beam radiotherapy 68 chlorambucil 68 SLNB 68 mycophenolate mofetil 68 gefitinib 68 colorectal liver metastases 68 renal tumors 68 chemoembolization 68 cisplatin 68 medically inoperable 68 EUS FNA 68 radiotherapy RT 68 androgen suppression 68 mRCC 68 pT2 68 sustained virological response 68 recurrent NSCLC 68 chemotherapeutic regimens 68 adriamycin 68 pertuzumab 68 HER2 negative 67 surgical debulking 67 unresectable 67 Flu Cy 67 CR nPR 67 follicular NHL 67 FDG PET 67 pelvic lymphadenectomy 67 recurrent GBM 67 distant metastasis 67 stage IIIA 67 XELOX 67 Trastuzumab 67 sunitinib 67 mCRC patients 67 chemotherapy docetaxel 67 cyclophosphamide 67 nonmetastatic 67 lymph node dissection 67 cisplatin chemotherapy 67 imatinib therapy 67 cytotoxic chemotherapy 67 advanced adenomas 67 adjuvant therapies 67 nab paclitaxel 67 Kaplan Meier analysis 67 goserelin 67 prostate carcinoma 67 radiochemotherapy 67 gemcitabine 67 radical cystectomy 67 gemcitabine carboplatin 67 BEACOPP 67 Adjuvant chemotherapy 67 radical prostatectomy RP 67 PSA nadir 67 dacarbazine 66 stage IIIb IV 66 docetaxel chemotherapy 66 estramustine 66 ALND 66 IV NSCLC 66 chemotherapy regimens 66 prostate cancer CaP 66 cytoreductive nephrectomy 66 Response Evaluation Criteria 66 FOLFIRI 66 peritoneal carcinomatosis 66 HSCT 66 R0 resection 66 decitabine 66 antiangiogenic therapy 66 recurrent prostate cancer 66 gefitinib Iressa 66 MGd 66 bortezomib 66 epithelial ovarian cancer 66 pemetrexed 66 micrometastases 66 bevacizumab Avastin 66 lymph node metastases 66 fluoropyrimidine 66 hepatic metastases 66 bleomycin 66 nephrectomy 66 5-fluorouracil/leucovorin 66 sorafenib Nexavar 66 #F FDG PET 66 liposomal doxorubicin 66 sentinel node biopsy 66 PCa 66 daunorubicin 66 gemcitabine Gemzar 66 cetuximab 66 prospectively defined 66 EGFR TKI 66 ErbB2 positive 66 KRAS mutations occur 66 fallopian tube cancers 66 standard chemotherapy regimen 66 ovarian carcinoma 65 bevacizumab Avastin ® 65 vandetanib 65 tumor shrinkage 65 breast carcinoma 65 FOLFOX6 65 anthracycline taxane 65 azacitidine 65 Fludara 65 trabectedin 65 heavily pretreated 65 Solid Tumors RECIST 65 HER2 positive cancers 65 F FDG PET 65 intravesical 65 lymph node metastasis 65 complete cytogenetic response 65 undetectable HBV DNA 65 5-FU/LV 65 FOLFOX 65 dose dexamethasone 65 KRAS status 65 plus dexamethasone 65 recurrent metastatic 65 GnRH agonists 65 RECIST Response Evaluation Criteria 65 remission induction 65 hormonal therapy 65 localized renal 65 vinorelbine 65 bevacizumab 65 squamous histology 65 lymph node involvement 65 Irinotecan 65 peginterferon 65 androgen suppression therapy 65 allogeneic stem cell 65 brain metastases 65 CRp 65 surrogate endpoint 65 CCyR 65 erlotinib Tarceva ® 65 dose cytarabine 65 ribavirin RBV 65 standard chemotherapy regimens 65 intravenous bisphosphonates 65 remission CR 65 carboplatin 65 differentiated thyroid 65 anastrozole 65 Recurrence Score 65 liver resection 65 temsirolimus 65 mitoxantrone 65 virologic response 65 epithelial tumors 65 NMIBC 65 Radical prostatectomy 65 SBRT 65 metastatic malignant melanoma 65 pegylated interferon alfa 2b 65 colorectal cancer liver metastases 65 peg interferon 65 RECIST criteria 65 platelet reactivity 64 locoregional disease 64 hypofractionated 64 platinum refractory 64 virological response 64 hepatectomy 64 SLN biopsy 64 chemotherapy regimen 64 underwent resection 64 evaluable 64 APTIVUS r 64 refractory AML 64 Lenalidomide 64 etoposide 64 HNSCC 64 doxorubicin docetaxel 64 univariate analysis 64 viral kinetics 64 oral clodronate 64 mitoxantrone chemotherapy 64 endocrine therapy 64 Accelerated Partial Breast Irradiation 64 sorafenib Nexavar ® 64 castration resistant prostate cancer 64 iodixanol 64 metastatic malignant 64 idarubicin 64 mg kg dose 64 evaluable patients 64 liver metastasis 64 Gemcitabine 64 contralateral breast 64 topotecan 64 adjuvant cisplatin 64 CHOP chemotherapy 64 xenograft models 64 octreotide LAR 64 FDG-PET/CT 64 pomalidomide 64 CR CRu 64 malignant pleural mesothelioma 64 node dissection 64 metastatic disease 64 Bezielle 64 mitomycin 64 adenoma recurrence 64 trastuzumab Herceptin ® 64 adalimumab 64 chemoresistant 64 operable breast cancer 64 urothelial carcinoma 64 cytogenetic response 64 pT3 64 KRAS mutation 64 orchiectomy 64 TTF Therapy 64 Zevalin consolidation 64 Taxotere ® 64 paclitaxel carboplatin 64 virologic failure 64 mapatumumab 64 docetaxel Taxotere 64 mitomycin C 64 oblimersen 64 sorafenib 64 endometrial carcinoma 64 imatinib 64 metastatic prostate cancer 64 irinotecan chemotherapy 64 myeloablative 64 bendamustine 64 thalidomide dexamethasone 64 fondaparinux 64 cytotoxic therapy 64 DMARD 64 Platinol ® 64 non squamous NSCLC 64 exemestane 64 HBeAg seroconversion 64 fallopian tube carcinoma 64 Platinol ® cisplatin 64 BCG refractory 64 metastatic CRC 64 elacytarabine 64 ixabepilone 64 hormone receptor positive 64 beta blocker therapy 64 SCCHN 64 biliary tract cancer 64 sipuleucel T 64 completely resected 64 TOP2A 64 doxorubicin 64 allogeneic SCT 63 multivariate Cox 63 eribulin mesylate 63 axillary nodes 63 hepatic resection 63 rituximab 63 CsA 63 pamidronate 63 abciximab 63 5 Fluorouracil 63 metastatic lesions 63 Capecitabine 63 FOLFIRINOX 63 prostate cancer CRPC 63 histologically proven 63 androgen ablation 63 Ceplene/IL-2 63 HIPEC 63 NSCLC 63 PEG IFN 63 alkylating agent 63 orthotopic 63 dexamethasone Decadron 63 Telintra 63 axillary node dissection 63 FOLPI 63 tirofiban 63 metastatic GIST 63 partial remissions 63 intraperitoneal chemotherapy 63 receptor tyrosine kinase inhibitor 63 thyroglobulin 63 HER2 overexpression 63 castrate resistant 63 anthracycline containing 63 infusional 5-FU/LV 63 melphalan 63 doxorubicin cyclophosphamide 63 darunavir ritonavir 63 specific antigen PSA 63 transurethral resection 63 chemo radiotherapy 63 superficial bladder cancer 63 alteplase 63 gemcitabine Gemzar ® 63 relapsed MM 63 metastatic pancreatic 63 resected 63 metastases 63 dasatinib 63 hormone refractory 63 seminal vesicle invasion 63 serum PSA 63 chemosensitivity 63 periprocedural 63 erlotinib 63 dacarbazine DTIC 63 olaparib 63 ZACTIMA 63 pneumonectomy 63 glycoprotein IIb IIIa inhibitors 63 radioiodine therapy 63 paclitaxel cisplatin 63 RECIST 63 advanced adenoma 63 cisplatin gemcitabine 63 CIMZIA ™ 63 intravesical therapy 63 complete remissions 63 lung metastasis 63 micrometastasis 63 complete cytogenetic 63 chemotherapeutic drug 63 paricalcitol 63 imetelstat 63 autologous transplant 63 median PFS 63 KRAS wild 63 trastuzumab Herceptin 63 Mitoxantrone 63 EGFR TKIs 63 chemotherapy cisplatin 63 RTOG 63 relapsed SCLC 63 #Gy 63 virologic responses 63 thoracoscopic lobectomy 63 radical prostatectomy 63 NSTE ACS 63 ALA PDT 63 bone metastasis 63 octreotide 63 antitumor effect 63 papillary renal cell carcinoma 63 unresectable tumors 63 liver transplant recipients 63 progression TTP 63 underwent surgical resection 63 TKI therapy 63 colorectal carcinoma 63 eplerenone 63 hematologic toxicity 63 DFMO 63 HER2 positive 63 patients undergoing CABG 63 fibrinolytic therapy 63 nodal dissection 63 hormone receptor negative 63 vorinostat 63 PegIFN RBV 63 PSMA ADC 63 imatinib Gleevec 63 zoledronic acid 63 adecatumumab 63 Platinol 62 ELACYT 62 methotrexate monotherapy 62 tenecteplase 62 Elitek 62 flutamide 62 ER CHOP 62 pharmacodynamic PD 62 sirolimus eluting stents 62 advanced unresectable 62 Folfox 62 epirubicin cyclophosphamide 62 cinacalcet 62 oral Xeloda 62 HGS ETR1 62 contralateral breast cancer 62 EFAPROXYN 62 lung metastases 62 endoscopic resection 62 metastatic HRPC 62 immunosuppressive regimen 62 univariate 62 antiplatelet therapy 62 evaluating tivozanib 62 invasive carcinoma 62 cabazitaxel 62 mutated KRAS 62 surgical resection 62 fulvestrant 62 fluvastatin 62 β blockers 62 axillary lymph node 62 esophagectomy 62 Pemetrexed 62 nodal metastasis 62 K ras mutations 62 multivariate analyzes 62 azathioprine 62 gemcitabine cisplatin 62 paclitaxel Taxol R 62 antithrombotic therapy 62 SUVmax 62 EGFR inhibitors 62 fludarabine 62 Free Survival PFS 62 advanced hepatocellular carcinoma 62 Solid Tumors criteria 62 unresectable stage 62 placebo dexamethasone 62 cediranib 62 relapsed ovarian cancer 62 preoperative radiotherapy 62 temozolomide 62 invasive ductal 62 allogeneic transplant 62 low dose cytarabine 62 TURBT 62 CA4P 62 Halaven 62 paclitaxel Taxol 62 mediastinoscopy 62 Erlotinib 62 dasatinib Sprycel ® 62 mutational status 62 hepatocellular carcinoma HCC 62 interferon alfa 62 NSABP B 62 docetaxel prednisone 62 IMGN# 62 tanespimycin 62 thromboembolic events 62 GP IIb IIIa inhibitors 62 tumor histology 62 androgen independent 62 metastatic lung cancer 62 tumor lysis syndrome 62 metachronous 62 situ LCIS 62 TIMP 1 62 axillary lymph node dissection 62 HER2 + 62 biologic therapy 62 ICD implantation 62 Natalizumab 62 dacarbazine chemotherapy 62 KRAS mutations 62 lobular carcinoma 62 rFSH 62 metastatic gastric 62 KRAS mutant tumors 62 Bortezomib 62 hepatocellular carcinoma 62 fibrinolytic 62 nephron sparing surgery 62 salpingo oophorectomy 62 bladder carcinoma 62 DOXIL 62 radiofrequency ablation RFA 62 dose melphalan 62 breast conserving 62 antithymocyte globulin 62 assessing T DM1 62 cisplatin resistant 62 metastatic castration resistant 62 achieved ACR# 62 capecitabine Xeloda 62 melphalan prednisone 62 Kaplan Meier method 62 cranial radiation 62 Chemophase 62 autologous SCT 62 endocrine therapies 62 5 FU leucovorin 62 LV dysfunction 62 perioperatively 62 fine needle aspiration 62 metastatic NSCLC 62 scintigraphic 62 HGPIN 62 intraperitoneal 62 Cetuximab 62 Adjuvant therapy 62 PegIFN 62 LHRH receptor positive 62 taxane chemotherapy 62 free survival PFS 62 axitinib 62 autologous stem cell 62 subgroup analyzes 62 clodronate 62 tumor regressions 62 intratumoral 62 prostate cancer PCa 62 GnRH agonist 62 prognostic indicator 62 Gliadel Wafer 62 refractory ovarian cancer 62 MAGE A3 ASCI 62 PROSTVAC VF 62 galiximab 62 Subgroup analysis 62 T1c 62 lung resection 62 perioperative mortality 62 metastatic bladder 61 letrozole 61 Mitomycin C 61 sustained virologic response 61 eptifibatide 61 platelet inhibitor 61 mg/m2 dose 61 neoadjuvant radiation 61 Allovectin 7 ® 61 recanalization 61 multivariable analysis 61 HBeAg positive patients 61 anti leukemic 61 HER2 expression 61 hepatocellular cancer 61 resection 61 transrectal ultrasound guided 61 trials RCTs 61 malignant lesions 61 intravesical infusion therapy 61 reinfarction 61 relapsing multiple sclerosis 61 EGFR expressing mCRC 61 nodal metastases 61 partial nephrectomy 61 patients evaluable 61 Degarelix 61 lenalidomide Revlimid R 61 interferon ribavirin 61 histological subtype 61 MabCampath 61 prospectively stratified 61 estrogen receptor negative 61 lenalidomide dexamethasone 61 balloon brachytherapy 61 #F FDG 61 EGFR mutation positive 61 receiving highly emetogenic 61 ganetespib 61 neurologic progression 61 Sentinel Lymph Node Biopsy 61 intracoronary 61 TroVax ® 61 CIMZIA TM 61 5 fluorouracil 61 pegfilgrastim 61 DAPT 61 basal cell carcinoma BCC 61 dasatinib Sprycel 61 adjuvant endocrine therapy 61 oral allopurinol 61 #.#ng/ml 61 IL#B 61 resected pancreatic cancer 61 nonsmall cell lung cancer 61 lymphocytosis 61 noninferiority 61 PROLARIS 61 mammographic density 61 abacavir lamivudine 61 fibrinolysis 61 PROCHYMAL 61 estrogen receptor ER 61 endosonography 61 lumbar spine BMD 61 aromatase inhibitor therapy 61 ELOXATIN 61 previously untreated follicular 61 prognostic biomarker 61 Torisel 61 BRCA deficient 61 postoperative morbidity 61 cranial irradiation 61 telaprevir dosed 61 Fludara ® 61 beam radiotherapy 61 urothelial bladder cancer 61 baseline LDH 61 methotrexate therapy 61 #mg/m# [001] 61 DMARDs 61 prostatectomy 61 iniparib 61 atypical hyperplasia 61 transarterial 61 progesterone receptor PR 61 alkylating agents 61 hormone deprivation 61 EGFR mutations 61 OPAXIO 61 achieve sustained virologic 61 Xanafide 61 OPCAB 61 hormone receptor status 61 bortezomib refractory 61 OncoVEX GM CSF 61 EGFR tyrosine kinase inhibitors 61 lipid lowering therapy 61 Herceptin trastuzumab 61 adenoma 61 temozolomide TMZ 61 thalidomide Thalomid 61 palliation 61 pulmonary metastases 61 intra arterial 61 invasive carcinomas 61 Amrubicin 61 response CCyR 61 infliximab 61 plasma uric acid 61 VELCADE melphalan 61 iniparib BSI 61 sentinel node 61 cyclophosphamide methotrexate 61 nonresponders 61 severe neutropenia 61 trastuzumab Herceptin R 61 GVAX 61 eribulin 61 lobectomy 61 advanced NSCLC 61 paclitaxel poliglumex 61 catheter angiography 61 Surgical resection 61 oral rivaroxaban 61 plus gemcitabine 61 cisplatin vinorelbine 61 estrogen receptor progesterone receptor 61 refractory prostate cancer 61 Pegasys plus Copegus 61 parathyroidectomy 61 prognostic variables 61 intravesical chemotherapy 61 histologically 61 evaluable subjects 61 chemotherapeutic agents 61 palifermin 61 dosage regimens 61 tamoxifen 61 core needle biopsy 61 thrombolytic therapy 61 leukemia AML 61 dutasteride 61 tumor necrosis 61 postoperative mortality 61 adjuvant hormonal therapy 61 everolimus eluting stents 61 rFVIIa 61 DAS# remission 61 oophorectomy 61 bicalutamide 61 paclitaxel Taxol ® 61 stage IIIB IV 61 invasive lobular carcinoma 61 Vectibix monotherapy 61 postoperative complication 61 undergoing coronary angiography 61 Aflibercept 61 Pegylated Liposomal Doxorubicin 61 unfractionated heparin 61 lipid lowering drugs 61 Cytoxan 61 precursor lesions 61 ritonavir boosted 60 immunosuppressive regimens 60 binary restenosis 60 refractory NSCLC 60 antiangiogenic agent 60 progesterone receptor negative 60 follicular lymphomas 60 endoscopic ultrasound 60 recurrent VTE 60 #mg/m# [002] 60 endocrine responsive 60 FDG uptake 60 BRAF mutation 60 enzastaurin 60 fosbretabulin 60 somatostatin analog 60 paclitaxel eluting stents 60 cilengitide 60 trans retinoic acid 60 ritonavir boosted lopinavir 60 metastatic breast cancer 60 prostate biopsy 60 BRCA2 mutation carriers 60 antibody titer 60 rhTSH 60 irinotecan doxorubicin oxaliplatin paclitaxel 60 interferon alfa 2a 60 laparoscopic radical nephrectomy 60 Kaplan Meier 60 haematologic 60 mucosal healing 60 sunitinib Sutent 60 coronary revascularization 60 Hazard Ratio 60 recurrent ovarian cancer 60 cervical carcinoma 60 seliciclib 60 adenomatous polyps 60 serum urate 60 hormonal therapies 60 BENICAR HCT 60 fludarabine cyclophosphamide 60 genotypic resistance 60 node metastases 60 EGFR expressing 60 colectomy 60 sleeve lobectomy 60 VATS lobectomy 60 PANVAC VF 60 preoperative PSA 60 intestinal metaplasia 60 metastatic sarcoma 60 CIN2 + 60 HoLEP 60 trastuzumab DM1 60 CaP 60 papillary thyroid carcinoma 60 alvespimycin 60 depsipeptide 60 thymoma 60 bone scintigraphy 60 Velcade bortezomib 60 Pegylated Interferon 60 relapsed refractory 60 ischemic cardiomyopathy 60 bilateral oophorectomy 60 SCIg 60 spontaneous bacterial peritonitis 60 multimodality therapy 60 pazopanib 60 comparator arm 60 TRUS biopsy 60 CANCIDAS 60 azacytidine 60 revascularization procedures 60 Tarceva TM 60 LHRH agonists 60 docetaxel Taxotere ® 60 taxanes 60 advanced neoplasia 60 GISTs 60 sarcomatoid 60 carotid stenosis 60 virological failure 60 logistic regression analysis 60 colorectal adenoma 60 Cisplatin 60 estrogen receptor positive 60 saline placebo 60 definite stent thrombosis 60 androgen blockade 60 nomograms 60 carcinoid tumors 60 certolizumab 60 mCi kg 60 CMV disease 60 extrapleural pneumonectomy 60 Peg IFN 60 Peginterferon 60 HER2 positive tumors 60 cetuximab Erbitux ® 60 natriuretic peptide 60 Her2/neu 60 tipranavir ritonavir 60 antiangiogenic 60 hematopoietic cancers 60 plus prednisone 60 sunitinib malate 60 teriflunomide 60 ERCC1 60 ACR# responses 60 tumors GIST 60 localized prostate cancer 60 chemotherapy gemcitabine 60 radiation chemoradiation 60 BRIM2 60 stereotactic radiotherapy 60 urothelial cancer 60 renal cell carcinomas 60 prednisone prednisolone 60 riociguat 60 neoadjuvant chemoradiotherapy 60 Adjuvant Therapy 60 pegylated liposomal doxorubicin PLD 60 FDG PET scans 60 ISF# 60 LMWH 60 abiraterone acetate 60 unfractionated heparin UFH 60 HER-2/neu 60 warfarin therapy 60 ibandronate 60 liposomal amphotericin B 60 symptomatic VTE 60 situ CIS 60 urine cytology 60 durable remissions 60 chemotherapeutic 60 Taxol ® 60 IFN beta 60 irinotecan 60 Chemoradiation 60 lymphovascular invasion 60 EpCAM 60 Renal Cell Carcinoma RCC 60 FIRMAGON 60 refractory multiple myeloma 60 EOquin 60 paclitaxel chemotherapy 60 mucinous 60 Cystectomy 60 pegylated interferon alfa 60 R# #mg BID 60 LEXIVA r 60 inotropic 60 postintervention 60 refractory colorectal cancer 60 clinicopathological features 60 histologic 60 STRIDE PD 60 chemotherapeutic regimen 60 metastatic HER2 negative 60 metastatic colorectal 60 antibiotic prophylaxis 60 transgene expression 60 coinfected patients 60 adenocarcinomas 60 splenectomized patients 60 esophageal carcinoma 60 preoperative staging 60 HBeAg 60 TURP 60 hepatic arterial 60 oncologic outcomes 60 TORISEL 60 Solid Tumours 60 metastatic 60 mCRC 60 cutaneous melanoma 60 metastatic hormone refractory 60 FOLFIRI alone 60 Solid Tumors 60 luteinizing hormone releasing 60 Thrombolysis 60 Neulasta ® 60 Bevacizumab 60 nonmetastatic prostate cancer 60 oral anticoagulation 60 prostate cancer HRPC 60 doublet chemotherapy 60 Subgroup analyzes 60 Thal Dex 60 transitional cell carcinoma 60 perioperative morbidity 60 tocilizumab 60 rt PA 60 allogeneic hematopoietic stem cell 60 antiandrogen 60 transarterial chemoembolization 60 randomized multicenter trial 60 EBMT criteria 60 EOquin TM 60 prior chemotherapy regimens 60 CC genotype 60 antimicrobial prophylaxis 60 hormone therapy estrogen 60 idraparinux 60 HER2 positive breast cancer 60 axillary node 60 Median survival 60 asymptomatic metastatic 60 histologic subtype 60 irbesartan 60 zalutumumab 60 chemotherapy FOLFOX 60 posaconazole 60 velafermin 60 nonoperative treatment 60 NAbs 60 renal dysfunction 60 PEGylated interferon beta 1a 60 FASLODEX 60 clinicopathological 60 non resectable 60 HRPC 59 low dose dexamethasone 59 nodular partial response 59 mTOR inhibitors 59 interferon alfa 2b 59 letrozole Femara 59 alfa 2a 59 metastatic renal cell 59 autologous transplantation 59 micafungin 59 cancer mCRC 59 Gefitinib 59 BRAF V#E mutation 59 syngeneic 59 farletuzumab 59 Percutaneous Coronary Intervention 59 Proxinium TM 59 endometrial cancers 59 metastatic kidney 59 intradermal injection 59 squamous cell carcinoma SCC 59 Paraplatin ® 59 Tesmilifene 59 serous ovarian cancer 59 dose cohorts 59 nomogram 59 endometrial hyperplasia 59 BEXXAR Therapeutic Regimen 59 BCIRG 59 LHRH 59 ipsilateral breast 59 prospectively randomized 59 adrenalectomy 59 androgen deprivation therapy 59 CBLC#